Back to Search
KENDALL ULBRICH, MD
MD
Neonatal-Perinatal Medicine Physician
NPI: 1326467069Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Neonatal-Perinatal Medicine PhysicianPrimary
Pediatrics — Neonatal-Perinatal Medicine
Code: 2080N0001X
036142667(IL)
Research & Publications (20)
Multifunctional cytotoxic stealth nanoparticles. A model approach with potential for cancer therapy.
PMID 19170551·Nano Lett·2009
8-other
Thermoresponsive, hydrolytically degradable polymer micelles intended for radionuclide delivery.
PMID 19554646·Macromol Biosci·2009
8-other
Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.
PMID 19166885·J Control Release·2009
8-other
HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
PMID 19632282·J Control Release·2009
7-preclinical
Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
PMID 18805484·Eur J Pharm Biopharm·2009
7-preclinical
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.
PMID 19304320·Biomaterials·2009
7-preclinical
Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.
PMID 19131551·Blood·2009
7-preclinical
Experimental verification of predicted beam-polarization oscillations near a spin resonance.
PMID 18352378·Phys Rev Lett·2008
8-other
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.
PMID 19238631·Br J Cancer·2008
7-preclinical
Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
PMID 18534705·J Control Release·2008
7-preclinical
Overcoming immunoescape mechanisms of BCL1 leukemia and induction of CD8+ T-cell-mediated BCL1-specific resistance in mice cured by targeted polymer-bound doxorubicin.
PMID 19047168·Cancer Res·2008
7-preclinical
Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
PMID 18325618·J Control Release·2008
7-preclinical
Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
PMID 18214996·J Gene Med·2008
7-preclinical
Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.
PMID 18220318·J Gene Med·2008
7-preclinical
New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
PMID 18304673·J Control Release·2008
7-preclinical
Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
PMID 18071336·Mol Ther·2008
7-preclinical
Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
PMID 17631976·J Control Release·2007
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2650 RIDGE AVE
EVANSTON, IL 60201 - Phone
- (847) 570-2530
Quick Facts
- NPI
- 1326467069
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile